Stockreport

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 [Yahoo! Finance]

Evaxion Biotech A/S - American Depositary Share  (EVAX) 
PDF Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01's already strong data pac [Read more]